This interview was conducted with Christopher Stephens, managing partner of Orrick, Herrington & Sutcliffe’s Asia offices with supporting responses from Xiang Wang, lead partner of the…
In Conversation
You’ve run a number of life sciences companies now, but before that you started Telephia, an information services provider to the wireless industry. How did you…
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the…
You have had significant experience at GSK and Pfizer, and also at Frontage Labs doing more entrepreneurial work. What ultimately brought you to Covance? I worked…
Could you please give us a brief introduction on CMBA? First and most obviously for new arrivals to our office, since 2011 we have changed locations,…
Your background before joining Beaufour Ipsen is quite unique among country managers of pharmaceutical companies: working many years in academia and focused very much on Asian…
In 2006, Genzyme’s global CEO, Henri Termeer, said he is “personally very interested in China” and that he expects the company to build a capable infrastructure…
What was the transition like from academia into entrepreneurship and what challenges did you face in beginning this company? I realized during this period in the…
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key…
“ "There is an ageing population [in China] with an epidemiological profile that is increasingly aligned with that of the West. These are elements that favor global… ”
Could you please give a brief introduction to the ABO and its history? ABO was established in 2005. The CRO business emerged in 2000 in China,…
You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company Xian-Janssen and then in the China National Pharmaceutical Group.…
